Cardiomyopathy in Duchenne muscular dystrophy

Article written and reviewed by Dr Luca Moretti

Duchenne muscular dystrophy is an X-linked dystrophinopathy in which near-complete loss of dystrophin damages skeletal muscle, diaphragm and myocardium in parallel. Cardiac involvement is not a late consequence of immobility, but a primary manifestation of the same molecular abnormality. Even a child without dyspnea, edema or reduced ejection fraction therefore has biologically vulnerable myocardium. Dystrophinopathy cardiomyopathy begins before it becomes clinically evident.

The cardiac phenotype evolves from subclinical electrocardiographic and mechanical abnormalities to focal necrosis, replacement fibrosis, regional dysfunction and finally dilated cardiomyopathy. The course is not uniform: age, variant, neuromuscular therapies, loading pressure, respiratory reserve and genetic modifiers contribute to marked individual variability. Loss of ambulation does not automatically indicate the cardiac stage, and severe muscle dysfunction may coexist with still-preserved ventricular function or with already advanced cardiac disease. Heart-muscle dissociation requires direct measurement of both organs.

The longer survival achieved with corticosteroids, assisted ventilation and multidisciplinary care has made cardiomyopathy an increasingly visible prognostic determinant. Symptoms nevertheless remain insensitive because motor limitation prevents the exertion that would normally reveal low output, while dyspnea, fatigue and sleep disorders may be attributed solely to the respiratory system. The modern goal is not to wait for heart failure, but to identify and treat preclinical cardiac injury throughout life.

DMD gene, dystrophin and genotype-phenotype correlations

The DMD gene, located at Xp21.2, comprises 79 coding exons distributed over approximately 2.2 megabases and is one of the largest human genes. The full-length muscle transcript produces Dp427 dystrophin, a subsarcolemmal protein linking cytoskeletal actin, the dystrophin-glycoprotein complex and the extracellular matrix. The amino-terminal domain, long central repeat region, cysteine-rich domain and carboxy-terminal end cooperate in fiber stability. The cytoskeleton-matrix bridge is not inert support but organizes signaling and the stress response.

Deletions of one or more exons are the most common class, followed by duplications and small nonsense, frameshift or splice variants. In general, a variant that disrupts the reading frame prevents production of functional dystrophin and causes Duchenne, whereas an in-frame deletion allows a shorter protein and more often leads to the Becker phenotype. The reading-frame rule has exceptions due to alternative splicing, internal initiation sites, transcript stability and function of residual domains. The reading-frame rule guides interpretation but does not replace clinical and protein characterization.

Molecular diagnosis should first assess exon deletions and duplications with a quantitative method, then small variants by sequencing the entire gene and relevant splice junctions. If suspicion remains strong, muscle RNA analysis or other techniques may demonstrate deep splice effects or unresolved rearrangements. A variant of uncertain significance does not by itself confirm disease and should be assessed with phenotype, segregation, transcript and, when truly necessary, immunohistochemistry. Complete genetic diagnosis is also essential for access to variant-dependent therapies.

Cardiac severity cannot be predicted with sufficient reliability from variant location alone. Associations between specific DMD regions and cardiomyopathy risk have been described, but cohorts, definitions and treatments differ, and the correlations do not justify reducing surveillance in an individual patient. Even brothers with the same mutation may develop fibrosis and dysfunction at different ages. The genotype does not replace imaging, because modifiers and the mechanical environment alter the trajectory.

Inheritance is X-linked. A substantial proportion of cases arise from de novo variants, but the absence of family history does not exclude maternal heterozygosity or germline mosaicism. Targeted testing for the familial variant, reproductive counseling and discussion of prenatal or preimplantation diagnosis should be separated from the woman's own cardiac assessment. Family counseling therefore includes both risk to offspring and risk of myocardial disease in the female carrier.

Pathobiology and myocardial pathology

In cardiomyocytes lacking dystrophin, the sarcolemma poorly tolerates cyclical contraction stress. Microinjury and mechanosensitive channels promote abnormal calcium influx, protease activation, reactive species generation, mitochondrial dysfunction and energy deficit. Disruption of the dystrophin-glycoprotein complex also displaces signaling proteins such as nitric oxide synthase and alters vascular and adrenergic responses. Primary mechanical injury therefore triggers a self-sustaining metabolic and inflammatory cascade.

Cardiomyocyte death recruits immune cells and activates fibroblasts, with collagen deposition and fibro-adipose replacement. Scar tissue reduces regional contractility, increases conduction heterogeneity and transfers load to surviving fibers, which undergo further stress. Angiotensin II, aldosterone and TGF-beta-mediated signaling participate in remodeling, providing the rationale for early neurohormonal blockade. Replacement fibrosis is both a consequence of necrosis and an amplifier of progression.

The classic macroscopic lesion begins in the posterobasal or inferolateral left ventricular wall, often from the subepicardial layers, and extends laterally. As disease advances, scar becomes more circumferential, may reach transmural myocardium and involve the septum, apex, papillary muscles and right ventricle. Wall thinning and regional aneurysms may precede obvious global dilation. The inferolateral topography differs from the subendocardial distribution of a coronary infarction.

Progression is not limited to an increase in focal collagen. Before late gadolinium enhancement appears, diffuse abnormalities of native T1, extracellular volume fraction, deformation and excitation-contraction coupling may develop. A CMR without LGE therefore does not demonstrate biologically normal myocardium, especially in a young child. The prefibrotic phase remains an important research area because treatment thresholds may precede visible scar.

The right ventricle is exposed both to dystrophin deficiency and to increased afterload caused by hypoventilation, hypoxemia, scoliosis and restrictive lung disease. In advanced stages, right ventricular dysfunction may limit drug therapy, ventricular assistance and transplantation, but is underestimated by difficult echocardiographic windows. Biventricular involvement should be measured directly and interpreted together with respiratory function.

Natural history and clinical cardiac phenotype

The earliest abnormalities may appear during childhood when the child has no cardiac symptoms. Sinus tachycardia, tall R waves in the right precordial leads, deep inferolateral Q waves, repolarization abnormalities or reduced strain may precede global dysfunction. Fibrosis on CMR can be documented even before age ten and its prevalence increases with age. Normal ejection fraction therefore does not exclude structural myocardial disease.

LGE and reduced deformation represent an intermediate phase in which cardiac output may remain adequate at rest. Inferolateral hypokinesia, increased end-systolic volumes and declining ejection fraction then appear; marked dilation may develop later than in other dilated cardiomyopathies. Scar progression is associated with systolic decline, but the rate and timing of transition vary. Serial remodeling is more informative than an isolated threshold.

Reduced ambulation masks exercise intolerance and functional class. A patient may not report dyspnea simply because he does not walk, while reduced use of the upper limbs, somnolence, poor appetite or greater dependence during transfers may be equivalents of low output. Orthopnea, edema, hepatomegaly and rapid weight gain are often late. Adapted clinical assessment evaluates changes from usual function, not only classic heart-failure symptoms.

Advanced heart failure may present with hypotension, persistent tachycardia, congestion, hyponatremia, worsening renal function or intracavitary thrombi. Serum creatinine is misleadingly low because of reduced muscle mass and may overestimate glomerular filtration; cystatin C and clinical trajectory help guide dosing of drugs and contrast. Natriuresis and weight must also be interpreted in the nutritional context. Hemodynamic fragility may appear before conventionally alarming laboratory values.

Corticosteroids and ventilation have modified natural history, but the cardiac effect of glucocorticoids cannot be separated from selection, duration, regimen and better respiratory function in many observational studies. Longer treatment duration has been associated with less fibrosis accumulation in some cohorts, without demonstrating complete protection. Neuromuscular benefit does not justify reducing cardiac treatment. Contemporary natural history reflects multiple interventions and does not match historical untreated cohorts.

Diagnosis, imaging and age-based surveillance

Cardiology assessment begins at the time of Duchenne diagnosis, regardless of age, with personal and family history, physical examination, blood pressure, ECG and echocardiography. Updated international standards support at least annual follow-up from childhood rather than waiting until age ten as in older protocols. New abnormalities, symptoms, gene therapy, surgery or respiratory decline require shorter intervals. Surveillance from diagnosis establishes a baseline before acoustic windows deteriorate.

Echocardiography measures dimensions, systolic and diastolic function, regurgitation, estimated pulmonary pressure and right ventricular function. Speckle tracking and longitudinal or circumferential strain may detect dysfunction before ejection fraction declines, but depend on image quality, software and pediatric reference values. Scoliosis, obesity, chest deformity and wheelchair positioning progressively degrade acoustic windows. Echocardiographic quality should be stated, avoiding interpretation of an incomplete study as normal.

Cardiac magnetic resonance is the reference for volumes and function and adds tissue characterization. LGE identifies focal scar, typically subepicardial inferolateral, while native T1, extracellular volume and T2 explore diffuse fibrosis and edema. Cine imaging and tagging or feature tracking quantify regional deformation. Multiparametric CMR separates injury, function and scar burden better than a single echocardiographic measure.

CMR is introduced when the child can complete it safely and without disproportionate sedation risk; the actual timing depends on cooperation, access and the clinical question. In experienced centers, rapid sequences and adaptations reduce the need for anesthesia. Gadolinium requires appropriate renal assessment, while noncontrast mapping retains information when contrast is contraindicated. Individual feasibility should become neither a rigid prohibition nor repeated sedation without decision-making impact.

Once LGE, reduced strain or dysfunction appears, the interval is individualized, often to six or twelve months, with quantitative comparison of the same metrics. CMR and echocardiography are not competitors: echo permits accessible, close follow-up, while CMR clarifies tissue and geometry at key decision points. Repetition should answer a question, such as whether to intensify treatment or assess progression. Continuity of measurements requires protocols and segmentation that are as comparable as possible.

The differential diagnosis includes myocarditis, exceptional ischemia, other genetic cardiomyopathies and drug toxicity. The typical LGE pattern is suggestive, but acute episodes with pain, ST elevation, very high troponin and edema on CMR may represent acute myocardial injury associated with Duchenne or intercurrent myocarditis. Coronary angiography or coronary CT is reserved for the clinical context and is not performed for every abnormal troponin value. Contextual interpretation of imaging avoids both an erroneous infarction diagnosis and automatic attribution of every event to the dystrophy.

ECG, biomarkers and arrhythmic risk

The typical ECG may show sinus tachycardia, a high R/S ratio in V1, narrow deep Q waves in lateral or inferior leads and ST-T abnormalities. These findings reflect myocardial loss and abnormal activation more than true right ventricular hypertrophy. Short PR intervals, conduction disturbances and bundle branch block may occur, especially in advanced stages. The electrocardiographic signature is a marker of involvement, not a surrogate measure of function.

Ventricular ectopy, nonsustained ventricular tachycardia, atrial arrhythmias and, more rarely, sustained tachycardia increase with dysfunction and fibrosis. In a large pediatric series, clinically significant Holter findings were uncommon with ejection fraction above 35 percent and much more common below that level. This does not negate the role of scar, but prevents using the Duchenne diagnosis alone as an indication for invasive procedures. Arrhythmic risk increases with structural deterioration.

Holter monitoring or prolonged patches are indicated with palpitations, syncope, ECG abnormalities, dysfunction, extensive LGE or before device decisions. Annual monitoring may be reasonable in an advanced phenotype, whereas yield is lower in children with normal function and the interval is individualized. Persistent sinus tachycardia should prompt investigation for fever, pain, anemia, dehydration, hypoventilation and heart failure before treatment. Targeted rhythm monitoring links arrhythmia, symptoms and myocardial stage.

Cardiac troponin I is preferable for assessing myocardial injury because troponin T and muscle isoforms may be less specific in neuromuscular diseases. Mild and intermittent elevations occur in DMD and may correlate with disease, but a dynamic increase, pain or ECG changes require a true acute-injury pathway. CK and CK-MB do not adequately distinguish heart from skeletal muscle. Serially interpreted troponin is more useful than a single value without a baseline.

BNP and NT-proBNP may remain low in the preclinical phase and do not exclude fibrosis or early dysfunction; they become more useful with congestion and longitudinal comparison. Complete blood count, electrolytes, liver function, cystatin C, albumin and iron status identify aggravating factors and limits to titration. After gene-transfer therapies, troponin I belongs to a specific safety protocol rather than routine isolated follow-up. The biomarker panel should change clinical decisions, not duplicate imaging.

Drug prevention and heart-failure therapy

ACE inhibitors are the foundation of early cardioprotection. In the small randomized perindopril study, started in boys with normal ventricular function, the benefit on dysfunction emerged during follow-up and the ten-year cohort showed lower mortality in the early-treatment group. Small sample size and prolonged analysis require caution, but the signal, antifibrotic rationale and cumulative experience support starting by approximately age ten in the absence of contraindications. Prophylactic ACE inhibition should not wait for dilation.

An ARB is an alternative in the event of cough or intolerance and is started before age ten if LGE, abnormal strain or dysfunction appears. Frequently low blood pressure, dehydration, infections and reduced renal reserve limit dosing, so titration follows tolerance rather than mechanically applied adult targets. Potassium and renal function should be checked after initiation and dose increases. The maximum tolerated dose is more realistic than a theoretical dose incompatible with the patient's physiology.

Adding eplerenone to an ACE inhibitor or ARB in boys with LGE and preserved ejection fraction attenuated worsening of strain in a small randomized trial. The AIDMD study subsequently showed noninferiority of spironolactone to eplerenone for stabilization of early indices over one year. These data support a mineralocorticoid receptor antagonist when myocardial injury appears, but do not by themselves demonstrate a certain survival effect. Mineralocorticoid protection requires monitoring of potassium, renal function and blood pressure.

A beta-blocker is added mainly with systolic dysfunction, persistent nonsecondary tachycardia or arrhythmias after renin-angiotensin blockade has been established. Disease-specific evidence consists mainly of observational data and small studies, while bradycardia, hypotension and reduced output reserve may prevent titration. A high heart rate may be compensatory in advanced heart failure and should not be suppressed without hemodynamic assessment. Beta-blocker titration follows function, rhythm and perfusion.

When ejection fraction falls, treatment is expanded according to principles for heart failure with reduced ejection fraction, adapted to age, weight, blood pressure and limited Duchenne-specific data. Sacubitril/valsartan and SGLT2 inhibitors may be considered by experienced centers in appropriate patients, but direct evidence remains far weaker than in common adult cardiomyopathy. Diuretics treat congestion without correcting natural history, and excess diuresis can compromise preload and renal function. Cautious therapeutic extrapolation distinguishes plausibility from demonstrated efficacy in DMD.

Anticoagulation is not routine for the diagnosis alone, but is indicated according to atrial fibrillation, intracavitary thrombus, embolism or severe dysfunction with individual risk. Digoxin and antiarrhythmic drugs have selective indications, considering interactions, renal function and conduction disease. Neuromuscular corticosteroids do not replace cardiac drugs, and abrupt withdrawal risks adrenal crisis. Multidisciplinary medication reconciliation prevents cardiology, neurology and pulmonology from independently changing an interdependent regimen.

Respiration, ventilation, anesthesia and systemic interactions

Diaphragmatic weakness, chest restriction, scoliosis and ineffective cough cause nocturnal hypoventilation before daytime respiratory failure. Hypoxia, hypercapnia and sleep fragmentation increase sympathetic activation and cardiopulmonary load, while respiratory infections may precipitate heart failure. Sitting and, when useful, supine spirometry, peak cough flow, respiratory pressures and sleep studies complete cardiac assessment. Integrated cardiorespiratory physiology explains why the same tachycardia may have different causes.

Nocturnal noninvasive ventilation and assisted cough improve gas exchange, sleep and survival and may reduce the hemodynamic stress associated with hypoventilation. They do not, however, halt dystrophin-deficiency myocardial necrosis and do not justify stopping ACE inhibitors or imaging. Conversely, good respiratory stability makes cardiac treatment, procedures and advanced support more tolerable. Timely ventilation is a component of cardiac care without being a molecular therapy for the heart.

Acute dyspnea requires differentiation among pneumonia, atelectasis, mucus plugging, aspiration, embolism, hypoventilation and congestion. Oxygen alone may correct saturation but worsen or conceal hypercapnia in a hypoventilating patient; when appropriate it should be combined with ventilatory support and CO2 monitoring. Empiric fluids may precipitate edema in a fragile ventricle, while excessive diuresis worsens secretions and perfusion. Emergency management must know the patient's respiratory and cardiac baseline.

Every procedure involving sedation or anesthesia requires a recent assessment of biventricular function, rhythm, ventilation, cough, airway and steroid therapy. Succinylcholine should be avoided because of the risk of rhabdomyolysis, hyperkalemia and cardiac arrest; volatile anesthetics are associated with anesthesia-induced rhabdomyolysis and their use requires specialist assessment, with intravenous techniques often preferred. This complication is not equivalent to a classic genetic predisposition to malignant hyperthermia. Disease-specific anesthetic safety should be recorded in emergency documentation.

Nondepolarizing neuromuscular blockers may have unpredictable duration and require quantitative monitoring; opioids and sedatives increase the risk of hypoventilation. Stress-dose steroids may be necessary in patients receiving chronic therapy, while planned extubation to noninvasive ventilation and assisted cough reduces respiratory failure. After major procedures, ECG, oxygen saturation, capnography and rhabdomyolysis surveillance are appropriate. Perioperative planning extends beyond the operating room.

Mutation-specific therapies and cardiac safety

Antisense oligonucleotides for exon skipping convert, in eligible variants, an out-of-frame transcript into an in-frame transcript and permit synthesis of truncated dystrophin. The principle derives from the Becker phenotype, but the quantity, distribution and quality of the protein produced vary. Currently available molecules target specific exons and a minority of patients; approvals and access differ among jurisdictions. Mutation-dependent therapy makes an exact genetic description essential.

Cardiac uptake of oligonucleotides does not necessarily match that in skeletal muscle. Increases in dystrophin in muscle biopsy and motor benefits do not automatically demonstrate prevention of fibrosis or heart failure, and clinical studies have not yet defined a robust long-term cardiac effect. Standard monitoring should therefore continue even in those receiving exon skipping. Distinct cardiac evidence prevents extrapolating to the myocardium endpoints measured in the biceps.

Systemic transfer with an adeno-associated viral vector uses a microdystrophin small enough to fit into the capsid. The protein retains selected domains but does not reproduce the entire Dp427, and its expression may be heterogeneous across muscles and cardiomyocytes. In the randomized phase 3 EMBARK trial, the difference between delandistrogene moxeparvovec and placebo in change in NSAA score at 52 weeks, the primary endpoint, was not statistically significant; some secondary functional endpoints favored treatment but do not demonstrate cardiac protection. Studies have emphasized ambulatory children and motor outcomes, leaving uncertainty about durability and protection of an already fibrotic heart. Cardiac microdystrophin is biologically promising but is not yet equivalent to cure of cardiomyopathy.

Immune response to the capsid or transgene, liver injury, thrombocytopenia, microangiopathy, myositis and myocarditis are relevant risks of AAV platforms. Troponin I may rise without symptoms or accompany rapid deterioration, especially with pre-existing cardiac disease. A dedicated consensus recommends baseline stratification and predefined cardiology surveillance after infusion. Post-transfer myocarditis should not be confused with ordinary dystrophinopathy progression.

Regulatory status is dynamic and nonuniform. In the United States, the indication for delandistrogene moxeparvovec was restricted in 2025 to ambulatory patients at least four years old with a confirmed DMD gene variant, and the prescribing information received a boxed warning for severe liver injury and liver failure, including fatal cases; the EMA issued a negative authorization opinion in 2025. Selection, contraindications, corticosteroids and monitoring must therefore follow the current product information at the place and time of care. Benefit-risk assessment cannot rely on an outdated regulatory indication.

Genome editing, new oligonucleotides, utrophin, fibrosis modulators and cell therapies remain experimental areas. CMR, strain, troponin and functional trajectory endpoints should be prespecified to demonstrate cardiac benefit, avoiding post hoc analyses in small subgroups. Motor improvement could even increase physical load on the heart if myocardial protection is less effective. Prospective cardiac research should accompany every systemic treatment for Duchenne muscular dystrophy.

Devices, LVAD and heart transplantation

An ICD indication for secondary prevention follows ventricular fibrillation or hemodynamically significant sustained ventricular tachycardia in the absence of a reversible cause. Primary prevention is more uncertain: thresholds derived from common dilated cardiomyopathy have not been validated in DMD, and fibrosis, nonsustained arrhythmias, function, syncope and overall life expectancy must be integrated. Implantation and shocks do not treat pump failure or respiratory arrest. The defibrillator decision requires realistic goals and anesthetic planning.

CRT may be considered with reduced ejection fraction, a wide QRS and appropriate dyssynchrony, but experience is limited and a typical left bundle branch block is not universal. Venous access, contractures, positioning and anesthesia increase procedural complexity. A pacemaker is indicated for clinically relevant bradyarrhythmias according to general principles, not for dystrophinopathy Q waves alone. Selective electrical therapy should provide a plausible functional benefit greater than the risk.

Referral for advanced heart failure should precede shock, irreversible renal injury and severe right ventricular failure. Hospitalizations, increasing diuretic requirement, hyponatremia, falling blood pressure, extensive LGE, worsening biventricular function and medication intolerance describe a trajectory more informative than ejection fraction alone. Traditional cardiopulmonary exercise testing is limited by weakness, but hemodynamics, imaging and daily function can define reserve. The window for advanced therapies is lost if assessment begins only with inotropes.

Continuous-flow LVADs have been implanted as destination therapy or bridge support in small numbers of adolescents and adults with Duchenne muscular dystrophy. Selection, chest anatomy, right ventricular function, ventilation, ability to manage the device, infection risk, caregivers and rehabilitation determine feasibility. Series show that prolonged support is possible, but bleeding, thrombosis, infection and technical dependence remain substantial. Personalized ventricular support is neither excluded by the diagnosis nor standard for every case of end-stage heart failure.

Heart transplantation was historically denied because of multisystem disease, but outcomes in selected muscular dystrophies and newer DMD experience challenge categorical exclusion. Candidacy requires achievable respiratory stability, compatible neuromuscular prognosis, support, nutrition and rehabilitation potential; non-ambulation alone does not imply futility. Immunosuppression and steroids may worsen weakness and infections. Individual transplant selection should assess benefit and burden without automatic diagnostic discrimination.

When ICD, LVAD or transplantation are not indicated or do not align with goals, specialist palliative care controls dyspnea, anxiety and congestion and facilitates decisions about ventilation and shocks. Deactivating ICD antitachycardia therapies may be appropriate in the terminal phase without stopping useful analgesia, ventilation or diuretics. Early discussion protects autonomy and family. Shared advance care planning is part of advanced cardiology, not therapeutic abandonment.

Females with a DMD variant and reproductive medicine

Describing all women as asymptomatic carriers is inaccurate. Random or skewed X-chromosome inactivation creates a mosaic of cardiomyocytes with and without dystrophin and may cause fibrosis even without weakness. Some women develop dilated cardiomyopathy, arrhythmias or heart failure, while rare girls manifest a Duchenne phenotype because of extreme skewing, monosomy X, translocations or other genetic configurations. Female cardiac risk is real and does not depend on having had an affected son.

When a pathogenic variant is identified, baseline ECG and imaging are indicated, ideally including at least one CMR if feasible. If assessment is normal, different consensus documents suggest periodic intervals of approximately three to five years, shortened with age, symptoms or findings; fibrosis or dysfunction requires regular cardiomyopathy follow-up. Inferolateral subepicardial LGE may precede decline in ejection fraction as in males. Carrier surveillance should not end after reproductive age.

Fibrosis or dysfunction justifies an ACE inhibitor or ARB and often a mineralocorticoid receptor antagonist, adapted to blood pressure and function. These drugs are contraindicated in pregnancy and require a preconception plan for replacement and monitoring. Pregnancy increases circulating volume and cardiac demand, while the postpartum period may destabilize reduced reserve. Cardio-obstetric assessment should precede conception in women with a DMD variant.

Genetic counseling explains that a heterozygous woman has a 50 percent probability of transmitting the variant in each pregnancy, with different consequences according to sex and expression. An affected man transmits his X chromosome to all daughters and to no sons. Mosaicism and de novo variants modify risk estimates in some families. Informed reproductive decision-making presents prenatal and preimplantation testing without turning them into prescriptions.

Transition, adult follow-up and prognosis

Transition is not merely transfer of a chart at age eighteen. It should begin in adolescence with identification of an adult cardiologist, pulmonologist, neurologist, physiatrist, anesthesiologist and heart-failure center, maintaining an overlap period. The summary includes variant, baseline CMR, functional trajectory, arrhythmias, ventilation, steroids, allergies and anesthetic precautions. Documented clinical continuity prevents the young adult from losing preventive care just as cardiac risk increases.

Adult follow-up remains at least annual and becomes every six months or more frequent with extensive fibrosis, dysfunction or treatment changes. Blood pressure, ECG, echo or CMR, rhythm, troponin in selected settings, natriuretic peptides, cystatin C, electrolytes and nutritional status are integrated with ventilation and upper-limb capacity. Telemonitoring of weight, heart rate or devices may help without replacing clinical visits. The multidimensional trajectory detects deterioration that a single ejection fraction would miss.

School, university, work and personal assistance should include a plan for medications, ventilator batteries, cardiac devices and urgent access to care. Syncope, chest pain, prolonged palpitations, rapid weight gain, orthopnea, edema, reduced urine output or a new ventilatory requirement need earlier reassessment. The family should not independently decide whether a symptom is cardiac or respiratory. The escalation network reduces delay in reaching a center capable of treating both components.

Prognosis has improved and many patients now reach adulthood, sometimes the fourth decade, through the combined effects of ventilation, corticosteroids, respiratory care and cardiac treatment. Historical averages cannot be mechanically applied to a child treated today and conceal major access differences. Extensive LGE, reduced biventricular function, tachycardia, arrhythmias, respiratory failure and hospitalizations better define individual risk. Contemporary prognosis should be updated with response and not communicated as an expiration date.

Quality of care depends on the ability to anticipate. Precise genetics, annual surveillance from diagnosis, CMR at key decision points, early neurohormonal blockade, appropriate ventilation and timely access to advanced heart-failure care form a single pathway. Molecular therapies add opportunities but also new questions about cardiac protection and safety. Longitudinal prevention remains the central principle until durable myocardial correction of dystrophin has been demonstrated.